Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATV-1601 in Advanced Solid Tumors and Breast Cancer
NCT07038369Phase 1Active, not recruiting
- Sponsor
- Atavistik Bio
- Start
- Jul 2025
- Primary completion
- Aug 2028
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 1, open-label trial of ATV-1601 in solid tumor and breast cancer (2 arms), sponsored by Atavistik Bio. Primary endpoints: Maximum plasma concentration at 48 months, Time to Maximum plasma concentration at 48 months and 8 more. Started Jul 2025; status: active, not recruiting.
02
Drugs
ATV-1601
03
Conditions
solid tumorbreast cancer
Beyond the preview
Go deeper on NCT07038369.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07038369.